Our approach to patients with relapsed or refractory follicular lymphoma and how we sequence the current FDA- approved agents in the 2L and beyond, with a specific focus on the sequencing of agents in patients with early relapse or primary refractory disease. len, lenalidomide; XRT, radiation.